Tiaki Therapeutics has appointed Suzanne Bruhn as CEO. Bruhn, a serial biotech CEO, arrives at Tiaki shortly after the Alzheimer’s disease startup entered into a collaboration with Eisai.
The Dementia Discovery Fund (DDF), an investment vehicle backed by seven big biopharma companies, formed and seeded Tiaki to support efforts to identify modulators of microglial function. Tiaki thinks targeting microglia, immune cells found in the brain, could lead to disease-modifying treatments for a range of neuroinflammatory conditions, starting with Alzheimer’s.
Angus Grant, PhD, CEO of the DDF and a member of Tiaki’s Board of Directors said, “Sue’s appointment comes at an exciting time for Tiaki, as we launch the company into drug discovery based on targets emerging from its systems biology platform. Her broad experience in drug development and company building will galvanize Tiaki’s progress toward novel treatments for dementia and neurodegenerative diseases.”
https://www.fiercebiotech.com/biotech/tiaki-hires-bruhn-as-ceo-for-alzheimer-s-drug-discovery-push
unknownx500
